COMPANY
Lighthouse Biotech provides pure, viable, and metabolically active tumor cells at any stage of the disease with advantageous timing and costs. In this way, it overcomes the limits of current liquid biopsy by enabling cutting-edge analysis in cancer research.
We strongly believe that minimally invasive diagnostics are the elective method to understand cancer, identify treatment, and improve the patient’s quality of life.
VISION
To enable clear identification, at any stage of cancer disease, of the best therapeutic choice for each patient.
MISSION
STRATEGY
To make the large-scale isolation of CTCs sustainable for research centers, oncology clinics, and pharmaceutical companies, on which to perform cutting-edge analysis to more rapidly
highlight the clinical utility of liquid biopsy, accelerate the development of precision medicine, and the transition to routine clinical practice.